Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

VPOWER GROUP INTERNATIONAL HOLDINGS LIMITED
偉能集團國際控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1608)

CHANGE OF CHAIRMAN OF THE BOARD, EXECUTIVE DIRECTOR AND COMPOSITION OF NOMINATION COMMITTEE

The Board announces that resolutions have been passed by the Board to effect the following changes with immediate effect on 7 July 2026:

1. Mr. Gao Zhan will resign as the chairman of the Board, an ED and the chairman of the Nomination Committee; and

2. Dr. Chen Shengguang will be appointed as the chairman of the Board, an ED and the chairman of the Nomination Committee.

RESIGNATION OF CHAIRMAN OF THE BOARD, EXECUTIVE DIRECTOR AND CHAIRMAN OF THE NOMINATION COMMITTEE

The board of directors (the "**Board**") of VPower Group International Holdings Limited (the "**Company**", and together with its subsidiaries, the "**Group**") announces that Mr. Gao Zhan ("**Mr. Gao**") has tendered his resignation as an executive director of the Company ("**ED**") due to his other work commitments and will cease to be the chairman of the Board and the chairman of the nomination committee of the Board (the "**Nomination Committee**") with immediate effect on 7 July 2026.

Mr. Gao has confirmed that he has no disagreement with the Board and there is no other matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company (the "**Shareholders**").

The Board would like to express its gratitude to Mr. Gao for his valuable contributions to the Company during his tenure of office.

APPOINTMENT OF CHAIRMAN OF THE BOARD, EXECUTIVE DIRECTOR AND CHAIRMAN OF THE NOMINATION COMMITTEE

The Board further announces that Dr. Chen Shengguang ("**Dr. Chen**") will be appointed as an ED, the chairman of the Board and the chairman of the Nomination Committee with immediate effect from 7 July 2026 to fill the casual vacancy arising from the resignation of Mr. Gao.

The biographical details of Dr. Chen are as follows:

Dr. Chen Shengguang, aged 46, has a sound professional background and rich experiences in finance, audit, investment and financing, and risk management. Dr. Chen successively served as the chief financial officer and a deputy general manager of China National Energy Engineering & Construction Co., Ltd. (中國能源工程股份有限公司) (a subsidiary of China General Technology (Group) Holding Co., Ltd. (中國通用技術(集團)控股有限責任公司) ("**Genertec**") which is the parent company of the controlling Shareholder i.e. China National Technical Import & Export Corporation (中國技術進出口集團有限公司)) from June 2013 to December 2019. He successively held the positions of deputy general manager and general manager of the investment & financing management department of China National Machinery Import and Export Corporation (中國機械進出口(集團)有限公司) (a subsidiary of Genertec) from December 2019 to April 2022. He worked as the general manager of the finance department of Genertec International Holding Co., Ltd. ("**Genertec International**", a subsidiary of Genertec) from May 2022 to September 2023. He then served as a deputy general manager of the audit & risk control department of Genertec from September 2023 to May 2024. Since May 2024, he has been serving as the chief financial officer of Genertec International.

Dr. Chen received his Ph.D. and a master's degree in public finance from Central University of Finance and Economics, the PRC, in June 2008 and June 2004, respectively. He obtained a bachelor's degree in public finance (taxation concentration) from Changchun Taxation College, the PRC, in July 2001.

Dr. Chen will enter into a director's service agreement as an executive director with the Company for a term commencing on 7 July 2026 and ending on 31 December 2028. Under the director's service agreement of Dr. Chen, he waives his right to receive remuneration from the Company as an ED during his term of office. Pursuant to the memorandum and articles of association of the Company, Dr. Chen will hold office as an ED until the forthcoming annual general meeting of the Company and will be subject to retirement by rotation and re-election at that meeting.

Save as disclosed above, as at the date of this announcement, Dr. Chen (i) does not hold any other positions within the Company and other members of the Group; (ii) did not hold any other directorships in public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) does not have any relationship with any directors, senior management, or substantial or controlling shareholders (as defined in the Rules Governing the Listing of Securities (the **"Listing Rules"**) on The Stock Exchange of Hong Kong Limited) of the Company; (iv) does not have any other major appointments or professional qualifications; and (v) does not have any interests in the shares or underlying shares of the Company and/or the associated corporations of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there is no other matter relating to the appointment of Dr. Chen that needs to be brought to the attention of the Shareholders, nor is there any information required to be disclosed pursuant to sub-paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules.

The Board would like to take this opportunity to welcome Dr. Chen to join the Board.

By Order of the Board
VPower Group International Holdings Limited
Chen Shengguang
Chairman

Hong Kong, 7 July 2026

As at the date hereof, the Board comprises Dr. Chen Shengguang, Mr. Lam Yee Chun, Mr. Liu Ruikun, Mr. Jin Jiantang and Mr. Wang Jiachang as executive directors; Mr. Wong Kwok Yiu as a non-executive director; and Mr. Suen Wai Yu, Dr. Wang Zheng and Dr. Lin Tun as independent non-executive directors.